Boris Schmidt

Summary

Country: Germany

Publications

  1. ncbi request reprint EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis
    Christina Grothusen
    Abt fuer Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    Arterioscler Thromb Vasc Biol 27:1184-90. 2007
  2. ncbi request reprint Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers
    Dierk Werner
    Department of Cardiology, Helios Hospital Schwerin, Schwerin, Germany
    Clin Pharmacokinet 47:323-32. 2008
  3. ncbi request reprint Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
    Boris Schmidt
    Clemens Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universitat Darmstadt, Petersenstrasse 22, Germany
    J Med Chem 46:2261-70. 2003
  4. ncbi request reprint Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179
    Christine Krämer
    Department of Cardiology, Medizinische Hochschule Hannover, Germany
    Circ Res 90:770-6. 2002
  5. ncbi request reprint Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites
    Michael Schupp
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Hypertension 47:586-9. 2006
  6. ncbi request reprint Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release
    Lusine Danielyan
    Department of Clinical Pharmacology, University Hospital of Tuebingen, Otfried Mueller Strasse 45, 72076 Tuebingen, Germany
    Neurochem Res 32:1489-98. 2007
  7. ncbi request reprint A frame shifted disulfide bridged analogue of angiotensin II
    Boris Schmidt
    TU Darmstadt, Institut for Organic Chemistry, Petersenstr 22, D 64287 Darmstadt, Germany
    Bioorg Med Chem 11:985-90. 2003
  8. ncbi request reprint Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells
    Izabela Młynarczuk-Biały
    Institut fuer Biochemie, Charite Universitaetsmedizin Berlin, Monbijoustrasse 2, 10117 Berlin, Germany
    Cancer Res 66:7598-605. 2006

Collaborators

  • Bernhard Schieffer
  • O Zolk
  • C H Gleiter
  • Th Unger
  • R H Boger
  • Ulrich Kintscher
  • L Danielyan
  • Maren Luchtefeld
  • Sumaira Umbreen
  • Dierk Werner
  • Christina Grothusen
  • Izabela Młynarczuk-Biały
  • Michael Schupp
  • Christine Krämer
  • Anton Grosch
  • Martin F Fromm
  • Ulrike Werner
  • Annett Meybaum
  • Heiko G Lestin
  • Bernhard Graf
  • Christian Schulz
  • Konstantinos Stellos
  • Ildiko Konrad
  • Omke Teebken
  • Meinrad Gawaz
  • Elisabeth Kremmer
  • Steffen Massberg
  • Jakub Gołąb
  • Nikolaj Frost
  • Peter M Kloetzel
  • Dirk Schadendorf
  • Lüder Wiebusch
  • Antje Ludwig
  • Christian Hagemeier
  • Lucas D Lee
  • Ulrike Kuckelkorn
  • Ulrike Seifert
  • Christina Montag
  • Heike Roeckmann
  • Michael Walden
  • Wolf Georg Forssmann
  • Dimitrios Tsikas
  • Jana Witte
  • Helmut Drexler
  • Julia Sunkomat

Detail Information

Publications8

  1. ncbi request reprint EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis
    Christina Grothusen
    Abt fuer Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    Arterioscler Thromb Vasc Biol 27:1184-90. 2007
    ..We investigated the impact of EXP3179, an active metabolite of the angiotensin II type 1 (AT1)-receptor antagonist Losartan (LOS) on GPVI-dependent platelet activation...
  2. ncbi request reprint Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers
    Dierk Werner
    Department of Cardiology, Helios Hospital Schwerin, Schwerin, Germany
    Clin Pharmacokinet 47:323-32. 2008
    ....
  3. ncbi request reprint Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
    Boris Schmidt
    Clemens Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universitat Darmstadt, Petersenstrasse 22, Germany
    J Med Chem 46:2261-70. 2003
  4. ncbi request reprint Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179
    Christine Krämer
    Department of Cardiology, Medizinische Hochschule Hannover, Germany
    Circ Res 90:770-6. 2002
    ..Serum levels of EXP3179 are detectable in patients in concentrations that exhibit antiinflammatory and antiaggregatory properties in vitro...
  5. ncbi request reprint Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites
    Michael Schupp
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Hypertension 47:586-9. 2006
    ..The present study characterizes the active losartan metabolite EXP3179 as a partial PPAR-gamma agonist. PPAR-gamma activation by EXP3179 may help us to understand the beneficial metabolic effects of losartan observed in clinical trials...
  6. ncbi request reprint Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release
    Lusine Danielyan
    Department of Clinical Pharmacology, University Hospital of Tuebingen, Otfried Mueller Strasse 45, 72076 Tuebingen, Germany
    Neurochem Res 32:1489-98. 2007
    ..These data suggest that AT1-R may decrease the susceptibility of astrocytes to hypoxic injury and their propensity to release TNF-alpha. AT1-R antagonists may therefore be of therapeutic value during hypoxia-associated neurodegeneration...
  7. ncbi request reprint A frame shifted disulfide bridged analogue of angiotensin II
    Boris Schmidt
    TU Darmstadt, Institut for Organic Chemistry, Petersenstr 22, D 64287 Darmstadt, Germany
    Bioorg Med Chem 11:985-90. 2003
    ..Theoretical conformational analysis was performed to compare the conformational characteristics of model compounds of c[Hcy(3,5)]Ang II and the frame shifted analogue c[NMGly(3,5)]Ang II in an attempt to explain the lack of affinity...
  8. ncbi request reprint Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells
    Izabela Młynarczuk-Biały
    Institut fuer Biochemie, Charite Universitaetsmedizin Berlin, Monbijoustrasse 2, 10117 Berlin, Germany
    Cancer Res 66:7598-605. 2006
    ..Thus, combined strategies targeting distinct proteolytic pathways may help to overcome mechanisms of drug resistance in tumor cells...